E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments

NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling

(2018) Zejun Fang et al.   CANCER LETTERS

Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility

(2017) Erik S Knudsen et al.   GUT

E2F-1 induced MCAK overexpression promotes the proliferation and gemcitabine resistance of pancreatic cancer cells

(2017) Yunpeng Peng et al.   PANCREATOLOGY

Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts

(2017) Rémy Nicolle et al.   Cell Reports

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Genetics and biology of pancreatic ductal adenocarcinoma

(2016) Haoqiang Ying et al.   GENES & DEVELOPMENT

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

Targeting the RB-E2F pathway in breast cancer

(2016) J Johnson et al.   ONCOGENE

Transcriptomic Analysis Predicts Survival and Sensitivity to Anticancer Drugs of Patients with a Pancreatic Adenocarcinoma

(2015) Pauline Duconseil et al.   AMERICAN JOURNAL OF PATHOLOGY

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

(2015) Richard A Moffitt et al.   NATURE GENETICS

The Molecular Signatures Database Hallmark Gene Set Collection

(2015) Arthur Liberzon et al.   Cell Systems

STRING v10: protein–protein interaction networks, integrated over the tree of life

(2014) Damian Szklarczyk et al.   NUCLEIC ACIDS RESEARCH

Nucleoside analog inhibits microRNA-214 through targeting heat-shock factor 1 in human epithelial ovarian cancer

(2013) Yi-Fei Chen et al.   CANCER SCIENCE

Targeting heat shock factor 1 with a triazole nucleoside analog to elicit potent anticancer activity on drug-resistant pancreatic cancer

(2012) Yi Xia et al.   CANCER LETTERS

An Efficient Mixed-Ligand Pd Catalytic System to Promote CN Coupling for the Synthesis of N-Arylaminotriazole Nucleosides

(2012) Yuting Fan et al.   CHEMISTRY-A EUROPEAN JOURNAL

A Novel Bitriazolyl Acyclonucleoside Endowed with Dual Antiproliferative and Immunomodulatory Activity

(2012) Yi Xia et al.   JOURNAL OF MEDICINAL CHEMISTRY

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

(2011) Eric A Collisson et al.   NATURE MEDICINE

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

N-Aryltriazole ribonucleosides with potent antiproliferative activity against drug-resistant pancreatic cancer

(2010) Yang Liu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A novel arylethynyltriazole acyclonucleoside inhibits proliferation of drug-resistant pancreatic cancer cells

(2010) Menghua Wang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Ligand-Mediated Highly Effective and Selective C−N Coupling for Synthesizing BioactiveN-Aryltriazole Acyclonucleosides

(2010) Yuting Fan et al.   ORGANIC LETTERS

Discovery of Novel Arylethynyltriazole Ribonucleosides with Selective and Effective Antiviral and Antiproliferative Activity

(2009) Jinqiao Wan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel Triazole Ribonucleoside Down-Regulates Heat Shock Protein 27 and Induces Potent Anticancer Activity on Drug-Resistant Pancreatic Cancer

(2009) Yi Xia et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Small-Molecule E2F Inhibitor Blocks Growth in a Melanoma Culture Model

(2008) Y. Ma et al.   CANCER RESEARCH

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE